Indicated for the treatment of foregut, midgut and hindgut neuroendocrine tumors, the radiopharmaceutical Bravnetsa is reportedly bioequivalent and therapeutically equivalent to the previously FDA-approved Lutathera.
|Articles|January 26, 2017
The New Healthcare Consumer - Riding The Sea Change
DROWNING IN HIGH DEDUCTIBLES?
It’s time to set a new course as consumers sail across the high seas on the healthcare horizon – but with the right customer service, it can be a cruise to better financial and administrative improvements.
Sponsored by:
ZirMed
888-884-7863
Related to this article
Newly cleared findings for the adjunctive AI platform a2z-Abdo-Triage include acute appendicitis, renal traumatic injury, ureteral stone and retroperitoneal hematoma.
In multivariable external testing, tumor structure habitat phenotypes from pre-treatment MRI revealed more than a doubling of recurrence risk for women with stage 2 and stage 3 breast cancer.
Could a la carte pricing be a consideration in improving revenue for radiologists in private practice?
Catch up on a variety of FDA news in radiology from the past week.
Catch up on the top radiology content of the past week.
Reportedly one of the first FDA-cleared chest X-ray AI software platforms derived from a foundation model, the Chest Xray software facilitates detection and localization of lung nodules, pneumothorax, mediastinal abnormalities and other thoracic abnormalities.
Incorporating structural MRI to improve PET imaging resolution, the MICSI-PET software also offers automated Centiloid quantification from amyloid PET scans.
Trending on Diagnostic Imaging
1
FDA Clears AI-Powered Triage Software for 10 Findings on Abdominopelvic CT
2
FDA Grants Final Approval of Emerging Radiopharmaceutical for GEP-NET Treatment
3
Can MRI-Derived Tumor Habitat Subregions Bolster Recurrence Risk Stratification in Stage 2 and 3 Breast Cancer Cases?
4
Is Private Practice Radiology as Important as an Amusement Park?
5